This viewpoint discusses skinny labeling's impact on drug prices, generic competition, and market entry issues, highlighting implications for affordability.
This Viewpoint discusses use of skinny labeling to reduce the price of brand-name drugs, impediments to timely generic market entry and affordability, and inducement liability that causes marketing uncertainty.
No takes yet. Share an insight, caveat, or question.
Tu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: